A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma
Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity.
Authors
- Bruce A. Littlefield
- Emanuele Mazzola (ORCID: https://orcid.org/0000-0003-0561-7336)
- Priscilla Merriam (ORCID: https://orcid.org/0000-0001-8675-998X)
- Lucille Sebastian
- Rosemary Anne Harrup (ORCID: https://orcid.org/0000-0002-9770-2791)
- D. Thomas
- Peter Grimison (ORCID: https://orcid.org/0000-0002-2653-1657)
- Mason Aberoumand (ORCID: https://orcid.org/0000-0003-0835-835X)
- Sally L. George (ORCID: https://orcid.org/0000-0003-2777-4922)
- E. Choy
- Michael Millward (ORCID: https://orcid.org/0000-0002-1744-1617)
- Mandy L. Ballinger (ORCID: https://orcid.org/0000-0002-9706-0514)
- David Espinoza
- Subotheni Thavaneswaran
- Frank Lin
- John P. Grady
- R. John. Simes
- Michael P. Brown
- Gregory M. Cote
- George Demetri
Institutions
- The University of Sydney (AU)
- Royal Adelaide Hospital (AU)
- Royal Hobart Hospital (AU)
- UNSW Sydney (AU)
- Chris O’Brien Lifehouse (AU)
- Migration Institute of Australia (AU)
- Dana-Farber Cancer Institute (US)
- Global Cancer Institute (US)
- Respiratory Clinical Trials (AU)
- The Kinghorn Cancer Centre (AU)
- Linear Clinical Research (AU)
- Eisai (Japan) (JP)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3362
- Primary Topic
- Vascular Tumors and Angiosarcomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00